Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10280-110001	Application No. 10/661,156
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR 1.98(b))		Applicant Sato et al.	
		Filing Date September 11, 2003	Group Art Unit 1656

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
AD	AA	5,851,999	12/22/1998	Ullrich et al.			
	AB	5,942,385	8/24/1999	Hirth			
	AC	6,040,157	3/21/2000	Hu et al.			
	AD	6,057,428	5/2/2000	Keyt et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
AD	AE	International Search Report, dated June 29, 2004.

Examiner Signature	/Anand Desai/	Date Considered	10/08/2006

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/661,156	ATTY. DOCKET NO.: D0617.70012US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: September 11, 2003	CONFIRMATION NO.: 6772
	APPLICANT: Sato et al.	
Sheet 1 of 4	GROUP ART UNIT: ~~1653~~ 1656	EXAMINER: Anand U. Desai

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document Number	U.S. Patent Document Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
AD	A1	5,766,860		Terman, B. et al.	06-16-1998
	A2	5,769,080		Matthijs, O. et al.	06-23-1998
	A3	5,773,024		Unger, E. et al.	02-30-1998
	A4	5,855,866		Thorpe, P. et al.	01-05-1999
	A5	5,861,301		Terman, B. et al.	09-03-1992
	A6	5,935,820		Hu, J. et al.	08-10-1999
	A7	6,051,230		Thorpe, P. et al.	04-18-2000
	A8	6,071,495		Unger, E. et al.	06-06-2000
	A9	6,146,657		Unger, E. et al.	11-14-2000
	A10	6,204,011		Kendall, R. et al.	03-20-2001
	A11	6,221,839		Alitalo, K. et al.	04-24-2001
	A12	6,245,530		Alitalo, K. et al.	06-12-2001
	A13	6,261,535		Thorpe, P. et al.	07-17-2001
	A14	6,261,537		Klaveness, J. et al.	07-17-2001
	A15	6,264,917		Klaveness, J. et al.	07-24-2001
	A16	6,322,770		Rajopadhye, M. et al.	11-27-2001
	A17	6,331,289		Klaveness, J. et al.	12-18-2001
	A18	6,359,115		Kendall, R. et al.	03-19-2002
	A19	6,361,946		Alitalo, K. et al.	08-06-1998
	A20	6,403,088		Alitalo, K. et al.	06-11-2002
	A21	6,451,764		Lee, J. et al.	09-17-2002
	A22	6,521,211		Unger, E. et al.	02-18-2003
	A23	6,576,608		Lee, J. et al.	06-10-2003
	A24	6,645,933		Alitalo, K. et al.	11-11-2003
	A25	6,689,352		Achen, M. et al.	02-10-2004
	A26	2001-0031485		Backer, M. et al.	10-18-2001
	A27	2001-0038842		Achen, M. et al.	11-08-2001
	A28	2002-0001566	A1	Rajopadhye, M. et al.	01-03-2002
	A29	2002-0015680	A1	Harris, T.	02-07-2002
	A30	2002-0065218		Achen, M. et al.	05-30-2002
	A31	2002-0068697		Tournaire, R. et al.	06-06-2002
	A32	2002-0086013		King, G.	07-04-2002
	A33	2002-0091082		Aiello, L.	07-11-2002

EXAMINER: /Anand Desai/	DATE CONSIDERED: 10/08/2006

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/661,156	ATTY. DOCKET NO.: D0617.70012US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: September 11, 2003	CONFIRMATION NO.: 6772
	APPLICANT: Sato et al.	
Sheet 2 of 4	GROUP ART UNIT: ~~1653~~ 1656	EXAMINER: Anand U. Desai

AD	A34	2002-0098187	A1	Ferrara, N. et al.	07-25-2002	
	A35	2002-0102260		Achen, M. et al.	08-01-2002	
	A36	2003-0023046		Ferrara, N. et al.	01-30-2003	
	A37	2003-0055006		Siemeister, G. et al.	03-20-2003	
	A38	2002-0058619		Tchistiakova, L. et al.	05-16-2002	
	A39	2003-0082103		Wartchow, C. et al.	05-01-2003	
	A40	2003-0091567		Alitalo, K. et al.	05-15-2003	
	A41	2003-0166523		Achen, M. et al.	09-04-2003	
	A42	2003-0176674		Rosen, D. et al.	09-18-2003	
	A43	2003-0180305	A1	Rajopadhye, M. et al.	11-27-2001	
	A44	2004-0033949		Bunting, S. et al.	02-19-2004	

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
AD	B1	EP	0 536 350	B1	American Cyanamid Company	08-07-2002	
	B2	EP	0 666 868	B1	Genentech, Inc.	04-03-2002	
	B3	EP	0 848 755	B1	Genentech, Inc.	06-11-2003	
	B4	EP	1 068 224	B1	Bristol-Myers Squibb Pharma Company	05-11-2005	
	B5	EP	1 238 986	A2	Genentech, Inc.	09-11-2002	
	B6	EP	1 166 798	A1	Schering Aktiengesellschaft	01-02-2002	
	B7	EP	1 166 799	A1	Schering Aktiengesellschaft	01-02-2002	
	B8	WO	94/10202	A1	Genentech, Inc.	05-11-1994	
	B9	WO	96/40285	A1	Imarx Pharmaceutical Corp.	12-19-1996	
	B10	WO	97/17442	A1	Immunex Corporation	05-15-1997	
	B11	WO	98/18498	A2	Nycomed Imaging AS	05-07-1998	
	B12	WO	98/18501	A2	Nycomed Imaging AS	05-07-1998	
	B13	WO	98/47541	A1	Nycomed Imaging AS	10-29-1998	
	B14	WO	99/29861	A1	Children's Medical Center Corporation	06-07-1999	
	B15	WO	99/40947	A2	Resolution Pharmaceuticals Inc.	08-19-1999	
	B16	WO	99/58162	A2	Du Pont Pharmaceuticals Company	11-18-1999	
	B17	WO	00/27414	A2	Basf Aktiengesellschaft	05-18-2000	
	B18	WO	00/45856	A2	Imarx Pharmaceutical Corp.	08-10-2000	
	B19	WO	01/42284	A2	Metris Therapeutics Limited	06-14-2001	
	B20	WO	01/54723	A1	Sunnybrook Health Science Center	08-02-2001	
	B21	WO	01/62942	A2	Ludwig Institute for Cancer Research	08-30-2001	

EXAMINER:	DATE CONSIDERED:
/Anand Desai/	10/08/2006

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/661,156	ATTY. DOCKET NO.: D0617.70012US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: September 11, 2003	CONFIRMATION NO.: 6772
	APPLICANT: Sato et al.	
Sheet 3 of 4	GROUP ART UNIT: ~~1653~~ 1656	EXAMINER: Anand U. Desai

AD	B22	WO	01/64235	A1	Ludwig Institute for Cancer Research	09-07-2001	
	B23	WO	01/70268	A1	Glaxo Group Limited	09-27-2001	
	B24	WO	01/70945	A1	Sibtech, Inc.	09-27-2001	
	B25	WO	01/82870	A2	Ludwig Institute for Cancer Research	11-08-2001	
	B26	WO	01/83693	A2	Glaxo Group Limited	11-08-2001	
	B27	WO	01/91805	A2	Bracco Research USA	12-06-2001	
	B28	WO	01/97850	A2	Schering Aktiengesellschaft	12-27-2001	
	B29	WO	02/07747	A1	Joslin Diabetes Center	01-31-2002	
	B30	WO	02/028895	A2	Commissariat a l'energie atomique	04-11-2002	Y-Abstract
	B31	WO	02/057299	A2	Ludwig Institute for Cancer Research	07-25-2002	
	B32	WO	02/060950	A2	Ludwig Institute for Cancer Research	08-08-2002	
	B33	WO	02/083849	A2	Human Genome Sciences, Inc.	10-24-2002	
	B34	WO	03/028643	A2	Targesome, Inc.	04-10-2003	
	B35	WO	03/074005	A2	Dyax Corp.	09-12-2003	
	B36	WO	03/094617	A2	Genentech, Inc.	11-20-2003	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
AD	C1	BIKFALVI et al., Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects. J Cell Physiol 149: 50-59, 1991.	
	C2	FAIRBROTHER et al., Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry 37(51): 17754-17764, 1998.	
	C3	FUKUMURA et al., Tumor induction of VEGF promoter activity in stromal cells. Cell 94: 715-725, 1998.	
	C4	HANAHAN et al., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.	
	C5	HOLMES et al., Site specific 1:1 opioid:albumin conjugate with in vitro activity and long in vivo duration. Bioconjug Chem 11: 439-444, 2000.	
	C6	KIM et al., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993.	
	C7	MELKKO et al., Encoded self-assembling chemical libraries. Nat Biotechnol. 2004 May;22(5):568-74.	
	C8	NEUFELD G et al., Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999.	
	C9	PEPPER et al., Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein. 1996;49(1-3):138-62.	
	C10	RISAU et al., Mechanisms of angiogenesis. Nature 386: 671-674, 1997.	

EXAMINER: /Anand Desai/	DATE CONSIDERED: 10/08/2006

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/661,156	ATTY. DOCKET NO.: D0617.70012US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: September 11, 2003	CONFIRMATION NO.: 6772
	APPLICANT: Sato et al.	
Sheet 4 of 4	GROUP ART UNIT: ~~1653~~ 1656	EXAMINER: Anand U. Desai

AD	C11	SCHAFFER et al., Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4435-9.	
	C12	STRAWN et al., Flk-1 as a target for tumor growth inhibition. Cancer Res 56: 3540-3545, 1996.	
	C13	THOMAS et al., A peptide sequence on carcinoembryonic antigen binds to a 80kD protein on Kupffer cells. Biochem Biophys Res Commun 188: 671-677, 1992.	
	C14	VEIKKOLA et al., Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60: 203-212, 2000.	
	C15	MATSUDAIRA et al., Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem. 1987 Jul 25;262(21):10035-8.	
	C16	ROBERTS M et al., Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2002 Jun 17;54(4):459-76.	
	C17	SLEEP et al., Saccharomyces cerevisiae strains that overexpress heterologous proteins. Biotechnology (N Y). 1991 Feb;9(2):183-7.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: /Anand Desai/	DATE CONSIDERED: 10/08/2006

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/661,156	ATTY. DOCKET NO.: D0617.70012US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: September 11, 2003	CONFIRMATION NO.: 6772
	APPLICANT: Sato et al.	
Sheet 1 of 4	GROUP ART UNIT: ~~1653~~ 1656	EXAMINER: Anand U. Desai

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document Number	U.S. Patent Document Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
AD	A45	5,547,656		Unger	08-20-1996
	A46	6,033,645		Unger et al.	03-07-2000
	A47	6,130,071		Alitalo et al.	10-10-2000
	A48	6,231,834	B1	Unger et al.	05-15-2001
	A49	6,245,318	B1	Klibanov et al.	06-12-2001
	A50	6,528,039	B2	Unger	03-04-2003
	A51	6,537,520	B1	Rajopadhye et al.	03-25-2003
	A52	6,548,048	B1	Cuthbertson et al.	05-14-2003
	A53	6,548,663	B1	Cheesman et al.	04-15-2003
	A54	6,610,269	B1	Klaveness et al.	08-26-2003
	A55	6,680,047	B2	Klaveness et al.	01-20-2004
	A56	6,730,658	B1	Alitalo et al.	05-04-2004
	A57	6,773,696	B2	Unger	08-10-2004
	A58	6,777,534	B1	Klagsbrun et al.	08-17-2004
	A59	6,818,220		Alitalo et al.	11-16-2004
	A60	6,841,367	B2	Kendall et al.	01-11-2005
	A61	6,841,382	B2	Kendall et al.	01-11-2005
	A62	6,875,741	B2	Pillutla et al.	04-05-2005
	A63	7,034,105	B2	Alitalo et al.	04-25-2006
	A64	2002-0010137	A1	Ashkenazi et al.	01-24-2002
	A65	2002-0037289	A1	Thorpe et al.	03-28-2002
	A66	2002-0102215	A1	Klaveness et al.	08-01-2002
	A67	2002-0164667	A1	Alitalo et al.	11-07-2002
	A68	2003-0027246	A1	Pedyczak et al.	02-06-2003
	A69	2003-0124120	A1	Harris	07-03-2003
	A70	2003-0149262	A1	Cheesman et al.	08-07-2003
	A71	2003-0157025	A1	Unger et al.	08-21-2003
	A72	2003-0166873	A1	Lee et al.	09-04-2003
	A73	2003-0180718	A1	Pillutla et al.	09-25-2003
	A74	2003-0236190	A1	Pillutla et al.	12-25-2003
	A75	2004-0009122	A1	Klaveness et al.	01-15-2004
	A76	2004-0023887	A1	Pillutla et al.	02-05-2004

EXAMINER:	DATE CONSIDERED:
/Anand Desai/	10/08/2006

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/661,156	ATTY. DOCKET NO.: D0617.70012US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: September 11, 2003	CONFIRMATION NO.: 6772
	APPLICANT: Sato et al.	
Sheet 2 of 4	GROUP ART UNIT: ~~1655~~ 1656	EXAMINER: Anand U. Desai

AD	A77	2004-0141922	A1	Klaveness et al.	07-22-2004
	A78	2004-0147448	A1	Alitalo et al.	07-29-2004
	A79	2004-0147449	A1	Siemeister et al.	07-29-2004
	A80	2004-0147726	A1	Alitalo et al.	07-29-2004
	A81	2004-0213790	A1	Lee et al.	10-28-2004
	A82	2004-0223911	A1	Bednarski et al.	11-11-2004
	A83	2004-0224398	A1	Anand-Apte	11-11-2004
	A84	2004-0248781	A1	Kerbel	12-09-2004
	A85	2004-0266694	A1	Tchistiakova et al.	12-30-2004
	A86	2005-0002865	A1	Klaveness et al.	01-06-2005
	A87	2005-0037967	A1	Rosenblum	02-17-2005
	A88	2005-0181995	A1	Kawai et al.	08-18-2005
	A89	2006-0003926	A1	Rajopadhye et al.	01-05-2006
	A90	2006-0008930	A1	Toyoda et al.	01-12-2006
	A91	2006-0078501	A1	Goertz et al.	04-13-2006

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
AD	B37	EP	0 580 726	B1	Unger	02-02-1994	
	B38	EP	0 627 940	B1	University of Texas	12-14-1994	
	B39	EP	0 711 127	B1	Unger	06-15-1996	
	B40	EP	0 804 932	A2	ImaRx Pharmaceutical Corp.	11-05-1997	
	B41	EP	1 064 376		Genentech, Inc.	01-03-2001	
	B42	EP	1 081 913	A2	Phillips Corporate Intellectual Property GmbH	03-07-2001	
	B43	EP	1 306 095	A2	University of Texas	05-02-2003	
	B44	EP	1 432 433		Novo Nordisk A/S	06-30-2004	
	B45	EP	1 519 193	A2	Ludwig Institute for Cancer Research	03-30-2005	
	B46	EP	1 574 518	A2	Nec Soft, Ltd.	09-14-2005	
	B47	EP	1 586 333	A2	Schering Aktiengesellschaft	10-19-2005	
	B48	WO	97/05250	A2	Helsinki University Licensing Ltd	02-13-1997	
	B49	WO	97/09427	A1	Genentech, Inc.	03-13-1997	

EXAMINER:	DATE CONSIDERED:
/Anand Desai/	10/08/2006

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/661,156	ATTY. DOCKET NO.: D0617.70012US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: September 11, 2003	CONFIRMATION NO.: 6772
	APPLICANT: Sato et al.	
Sheet 3 of 4	GROUP ART UNIT: ~~1655~~ 1656	EXAMINER: Anand U. Desai

AD	B50	WO	98/18495	A2	Nycomed Imaging AS	05-07-1998	
	B51	WO	98/18500	A2	Nycomed Imaging AS	05-07-1998	
	B52	WO	98/33917	A1	The Ludwig Institute for Cancer Research	08-06-1998	
	B53	WO	98/58053	A1	Kendall	12-23-1998	
	B54	WO	99/55383	A2	Nycomed Imaging AS	11-04-1999	
	B55	WO	00/63380	A1	Genentech, Inc.	10-26-2000	
	B56	WO	01/52875	A1	Ludwig Institute for Cancer Research	07-26-2001	
	B57	WO	01/57067	A1	Supratek Pharma Inc.	08-09-2001	
	B58	WO	02/16412	A2	Dyax Corp.	02-28-2002	
	B59	WO	02/72011	A2	Targesome, Inc.	09-19-2002	
	B60	WO	02/96367	A2	Targesome, Inc.	12-05-2002	
	B61	WO	03/035839	A2	DGI Biotechnologies, Inc.	05-01-2003	
	B62	WO	03/070747	A2	Novo Nordisk A/S	08-28-2003	
	B63	WO	03/084574	A1	Bracco International BV	10-16-2003	
	B64	WO	03/103581	A2	Genentech, Inc.	12-18-2003	
	B65	WO	2004/001064	A2	Dyax Corporation	12-31-2003	
	B66	WO	2004/058802	A1	Amersham Health AS	07-15-2004	
	B67	WO	2004/058803	A2	Amersham Health AS	07-15-2004	
	B68	WO	2004/064595	A2	Bracco International BV	08-05-2004	
	B69	WO	2004/065621	A1	Dyax Corp.	08-05-2004	
	B70	WO	2004/085617	A2	The Cleveland Clinic Foundation	10-07-2004	
	B71	WO	2004/108074	A2	Research Development Foundation	12-16-2004	
	B72	WO	2005/011722	A2	Ludwig Institute for Cancer Research	02-10-2005	
	B73	WO	2005/016963	A2	Ludwig Institute for Cancer Research	02-24-2005	
	B74	WO	2005/070472	A2	Sunnybrook and Women's College Health Sciences Centre	08-04-2005	
	B75	WO	2005/072417	A2	The Ohio State University Research Foundation	08-11-2005	
	B76	WO	2006/015385	A2	Sopherion Therapeutics, Inc.	02-09-2006	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
AD	C18	BINETRUY-TOURNAIRE et al., Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 2000 Apr 3;19(7):1525-33.	
AD	C19	HARVATH et al., Laminin peptides stimulate human neutrophil motility. J Immunol. 1994 Jun 1;152(11):5447-56.	

EXAMINER: /Anand Desai/	DATE CONSIDERED: 10/08/2006

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/661,156	ATTY. DOCKET NO.: D0617.70012US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: September 11, 2003	CONFIRMATION NO.: 6772
	APPLICANT: Sato et al.	
Sheet 4 of 4	GROUP ART UNIT: ~~1653~~ 1656	EXAMINER: Anand U. Desai

AD	C20	IWAMOTO et al., YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science. 1987 Nov 20;238(4830):1132-4.	
	C21	JIA et al., Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF. Biochem Biophys Res Commun. 2001 Apr 27;283(1):164-73.	
	C22	LECOUTER et al., Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature. 2001 Aug 30;412(6850):877-84.	
	C23	SATO et al., Development of mammalian serum albumin affinity purification media by peptide phage display. Biotechnol Prog. 2002 Mar-Apr;18(2):182-92.	
	C24	SHRIVASTAVA et al., A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. Protein Eng Des Sel. 2005 Sep;18(9):417-24.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: /Anand Desai/	DATE CONSIDERED: 10/08/2006

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.